Myriad Genetics, Inc. (MYGN)
USD 7.56
(6.03%)
USD 7.56
(6.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -123.7 Million USD | -154.0% |
| 2021 | -48.7 Million USD | 75.0% |
| 2020 | -194.8 Million USD | -2663.16% |
| 2019 | 7.6 Million USD | 0.0% |
| 2018 | 7.6 Million USD | -93.6% |
| 2017 | 118.7 Million USD | 140.28% |
| 2016 | 49.4 Million USD | -70.38% |
| 2015 | 166.8 Million USD | 24.29% |
| 2014 | 134.2 Million USD | -51.1% |
| 2013 | 274.44 Million USD | 20.37% |
| 2012 | 228 Million USD | 26.44% |
| 2011 | 180.31 Million USD | 14.29% |
| 2010 | 157.77 Million USD | 16.81% |
| 2009 | 135.07 Million USD | 6.81% |
| 2008 | 126.46 Million USD | 232.09% |
| 2007 | 38.08 Million USD | 179.79% |
| 2006 | -47.72 Million USD | -4.69% |
| 2005 | -45.58 Million USD | -11.89% |
| 2004 | -40.74 Million USD | 4.43% |
| 2003 | -42.63 Million USD | -55.91% |
| 2002 | -27.34 Million USD | -46.55% |
| 2001 | -18.65 Million USD | -42.05% |
| 2000 | -13.13 Million USD | -13.76% |
| 1999 | -11.54 Million USD | 6.88% |
| 1998 | -12.4 Million USD | 4.62% |
| 1997 | -13 Million USD | -4.0% |
| 1996 | -12.5 Million USD | -40.45% |
| 1995 | -8.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -113.7 Million USD | -117.82% |
| 2023 Q1 | -52.2 Million USD | -13.48% |
| 2023 Q3 | -60.1 Million USD | 47.14% |
| 2022 Q3 | -45 Million USD | -152.81% |
| 2022 Q2 | -17.8 Million USD | -19.46% |
| 2022 Q4 | -46 Million USD | -2.22% |
| 2022 Q1 | -14.9 Million USD | 65.43% |
| 2022 FY | -123.7 Million USD | -154.0% |
| 2021 Q3 | -79.9 Million USD | -284.13% |
| 2021 FY | -48.7 Million USD | 75.0% |
| 2021 Q2 | -20.8 Million USD | 55.46% |
| 2021 Q1 | -46.7 Million USD | 3.11% |
| 2021 Q4 | -43.1 Million USD | 46.06% |
| 2020 Q2 | -68.3 Million USD | 48.92% |
| 2020 FY | -194.8 Million USD | -2663.16% |
| 2020 Q3 | -39.6 Million USD | 42.02% |
| 2020 Q4 | -48.2 Million USD | -21.72% |
| 2020 Q1 | -133.7 Million USD | -1419.32% |
| 2019 Q3 | -20.9 Million USD | -273.21% |
| 2019 FY | 7.6 Million USD | 0.0% |
| 2019 Q1 | 5.9 Million USD | -3.28% |
| 2019 Q4 | -8.8 Million USD | 57.89% |
| 2019 Q2 | -5.6 Million USD | -194.92% |
| 2018 Q1 | 17 Million USD | 286.36% |
| 2018 FY | 7.6 Million USD | -93.6% |
| 2018 Q2 | 15.9 Million USD | -6.47% |
| 2018 Q3 | 1.2 Million USD | -92.45% |
| 2018 Q4 | 6.1 Million USD | 408.33% |
| 2017 Q1 | 12.9 Million USD | -2.27% |
| 2017 FY | 118.7 Million USD | 140.28% |
| 2017 Q4 | 4.4 Million USD | -94.97% |
| 2017 Q3 | 87.4 Million USD | 411.11% |
| 2017 Q2 | 17.1 Million USD | 32.56% |
| 2016 FY | 49.4 Million USD | -70.38% |
| 2016 Q2 | 35.7 Million USD | -16.2% |
| 2016 Q3 | 6.2 Million USD | -82.63% |
| 2016 Q4 | 13.2 Million USD | 112.9% |
| 2016 Q1 | 42.6 Million USD | -5.75% |
| 2015 FY | 166.8 Million USD | 24.29% |
| 2015 Q3 | 43.3 Million USD | 19.61% |
| 2015 Q4 | 45.2 Million USD | 4.39% |
| 2015 Q2 | 36.2 Million USD | 1.29% |
| 2015 Q1 | 35.74 Million USD | -1.66% |
| 2014 Q3 | 25.92 Million USD | -51.32% |
| 2014 Q4 | 36.34 Million USD | 40.21% |
| 2014 Q1 | 55.28 Million USD | -33.39% |
| 2014 FY | 134.2 Million USD | -51.1% |
| 2014 Q2 | 53.25 Million USD | -3.68% |
| 2013 Q2 | 65.91 Million USD | 13.81% |
| 2013 Q3 | 82.9 Million USD | 25.77% |
| 2013 Q4 | 82.99 Million USD | 0.11% |
| 2013 FY | 274.44 Million USD | 20.37% |
| 2013 Q1 | 57.91 Million USD | 4.2% |
| 2012 FY | 228 Million USD | 26.44% |
| 2012 Q1 | 46.09 Million USD | 1.39% |
| 2012 Q2 | 47.28 Million USD | 2.58% |
| 2012 Q3 | 48.58 Million USD | 2.74% |
| 2012 Q4 | 55.58 Million USD | 14.42% |
| 2011 Q4 | 45.46 Million USD | 9.63% |
| 2011 Q1 | 41.82 Million USD | 8.39% |
| 2011 FY | 180.31 Million USD | 14.29% |
| 2011 Q3 | 41.47 Million USD | -0.73% |
| 2011 Q2 | 41.77 Million USD | -0.11% |
| 2010 FY | 157.77 Million USD | 16.81% |
| 2010 Q4 | 38.58 Million USD | 8.42% |
| 2010 Q3 | 35.59 Million USD | -5.38% |
| 2010 Q2 | 37.61 Million USD | 13.21% |
| 2010 Q1 | 33.22 Million USD | -3.76% |
| 2009 FY | 135.07 Million USD | 6.81% |
| 2009 Q1 | 22.31 Million USD | 25.58% |
| 2009 Q3 | 29.71 Million USD | -59.34% |
| 2009 Q2 | 73.07 Million USD | 227.52% |
| 2009 Q4 | 34.52 Million USD | 16.19% |
| 2008 Q3 | 13.31 Million USD | -79.9% |
| 2008 FY | 126.46 Million USD | 232.09% |
| 2008 Q4 | 17.76 Million USD | 33.46% |
| 2008 Q2 | 66.21 Million USD | 947.16% |
| 2008 Q1 | -7.81 Million USD | 10.53% |
| 2007 FY | 38.08 Million USD | 179.79% |
| 2007 Q4 | -8.73 Million USD | 24.57% |
| 2007 Q3 | -11.58 Million USD | 5.58% |
| 2007 Q2 | -12.26 Million USD | -34.91% |
| 2007 Q1 | -9.09 Million USD | -179.97% |
| 2006 FY | -47.72 Million USD | -4.69% |
| 2006 Q2 | -13.98 Million USD | -16.96% |
| 2006 Q1 | -11.95 Million USD | -24.52% |
| 2006 Q3 | -15 Million USD | -7.29% |
| 2006 Q4 | 11.36 Million USD | 175.79% |
| 2005 Q4 | -9.6 Million USD | 4.51% |
| 2005 FY | -45.58 Million USD | -11.89% |
| 2005 Q3 | -10.05 Million USD | -15.01% |
| 2005 Q2 | -8.74 Million USD | 18.38% |
| 2005 Q1 | -10.71 Million USD | -0.32% |
| 2004 Q2 | -10.92 Million USD | 2.17% |
| 2004 Q1 | -11.16 Million USD | -7.54% |
| 2004 Q4 | -10.67 Million USD | -0.56% |
| 2004 Q3 | -10.61 Million USD | 2.79% |
| 2004 FY | -40.74 Million USD | 4.43% |
| 2003 Q2 | -7.67 Million USD | -25.58% |
| 2003 Q3 | -10.16 Million USD | -32.5% |
| 2003 Q4 | -10.38 Million USD | -2.09% |
| 2003 FY | -42.63 Million USD | -55.91% |
| 2003 Q1 | -6.11 Million USD | 18.4% |
| 2002 Q4 | -7.48 Million USD | -23.34% |
| 2002 FY | -27.34 Million USD | -46.55% |
| 2002 Q1 | -4.44 Million USD | -17.43% |
| 2002 Q2 | -7.46 Million USD | -68.11% |
| 2002 Q3 | -6.07 Million USD | 18.69% |
| 2001 Q4 | -3.78 Million USD | -27.48% |
| 2001 Q3 | -2.96 Million USD | 14.1% |
| 2001 Q1 | -3.25 Million USD | -1.67% |
| 2001 Q2 | -3.45 Million USD | -6.03% |
| 2001 FY | -18.65 Million USD | -42.05% |
| 2000 Q1 | -3.02 Million USD | -31.43% |
| 2000 Q2 | -3.5 Million USD | -15.95% |
| 2000 FY | -13.13 Million USD | -13.76% |
| 2000 Q3 | -3.22 Million USD | 8.13% |
| 2000 Q4 | -3.2 Million USD | 0.49% |
| 1999 Q2 | -3 Million USD | -15.38% |
| 1999 Q1 | -2.6 Million USD | 27.78% |
| 1999 Q4 | -2.3 Million USD | 14.81% |
| 1999 FY | -11.54 Million USD | 6.88% |
| 1999 Q3 | -2.7 Million USD | 10.0% |
| 1998 Q4 | -3.6 Million USD | -5.88% |
| 1998 FY | -12.4 Million USD | 4.62% |
| 1998 Q2 | -3.8 Million USD | -8.57% |
| 1998 Q3 | -3.4 Million USD | 10.53% |
| 1998 Q1 | -3.5 Million USD | -12.9% |
| 1997 Q4 | -3.1 Million USD | -14.81% |
| 1997 Q2 | -500 Thousand USD | 87.5% |
| 1997 Q3 | -2.7 Million USD | -440.0% |
| 1997 FY | -13 Million USD | -4.0% |
| 1997 Q1 | -4 Million USD | 6.98% |
| 1996 Q1 | -2.7 Million USD | -42.11% |
| 1996 FY | -12.5 Million USD | -40.45% |
| 1996 Q2 | -2.9 Million USD | -7.41% |
| 1996 Q3 | -3.7 Million USD | -27.59% |
| 1996 Q4 | -4.3 Million USD | -16.22% |
| 1995 Q4 | -1.9 Million USD | -290.0% |
| 1995 FY | -8.9 Million USD | 0.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -27.058% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -1029.341% |
| Aspira Women's Health Inc. | -18.85 Million USD | -556.164% |
| Biodesix, Inc. | -41.34 Million USD | -199.211% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -4669.455% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1451.442% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -1451.442% |
| Bionano Genomics, Inc. | -215.24 Million USD | 42.531% |
| CareDx, Inc | -101.9 Million USD | -21.394% |
| Check-Cap Ltd. | -19.28 Million USD | -541.365% |
| Castle Biosciences, Inc. | -67.97 Million USD | -81.973% |
| DarioHealth Corp. | -56.18 Million USD | -120.15% |
| Exact Sciences Corporation | -215.01 Million USD | 42.468% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -70.163% |
| Guardant Health, Inc. | -564.72 Million USD | 78.096% |
| ICON Public Limited Company | 956.15 Million USD | 112.937% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 111.275% |
| Illumina, Inc. | -1.06 Billion USD | 88.428% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -1102.936% |
| iSpecimen Inc. | -11.16 Million USD | -1007.495% |
| Standard BioTools Inc. | -76.6 Million USD | -61.488% |
| MDxHealth SA | -27.32 Million USD | -352.666% |
| 23andMe Holding Co. | -321.35 Million USD | 61.507% |
| Medpace Holdings, Inc. | 336.82 Million USD | 136.725% |
| Mainz Biomed B.V. | -26.64 Million USD | -364.258% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -1075.773% |
| NeoGenomics, Inc. | -107.73 Million USD | -14.818% |
| Neogen Corporation | 58.66 Million USD | 310.865% |
| Inotiv, Inc. | -81.46 Million USD | -51.854% |
| Natera, Inc. | -446.24 Million USD | 72.28% |
| OPKO Health, Inc. | -157.02 Million USD | 21.221% |
| Psychemedics Corporation | -2.92 Million USD | -4134.851% |
| Prenetics Global Limited | -52.51 Million USD | -135.558% |
| Prenetics Global Limited | -52.51 Million USD | -135.558% |
| Precipio, Inc. | -7.62 Million USD | -1523.36% |
| Personalis, Inc. | -109.93 Million USD | -12.52% |
| RadNet, Inc. | 98.69 Million USD | 225.333% |
| Sera Prognostics, Inc. | -39.82 Million USD | -210.64% |
| Sotera Health Company | 276.69 Million USD | 144.707% |
| Neuronetics, Inc. | -30.55 Million USD | -304.857% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -2746.295% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -2746.295% |
| Trinity Biotech plc | -27.04 Million USD | -357.386% |
| Twist Bioscience Corporation | -220.83 Million USD | 43.984% |
| Exagen Inc. | -22.83 Million USD | -441.665% |